Table 1.
Selected RCTs for systemic chemotherapy of advanced colorectal cancer
| Author, year | Pat. [n] | Treatment regimen | Median PFS [months] | Median OS [months] |
|---|---|---|---|---|
| DeGramont, 2000 [15] |
210 |
FOLFOX4 |
9.0 |
16.2 |
| Giacchetti, 2000 [16] |
100 |
FOLFOX |
8.7 |
19.4 |
| Douillard, 2000 [17] |
199 |
FOLFIRI |
6.7 |
17.4 |
| Saltz, 2000 [18] |
226 |
IFL |
7.0 |
14.8 |
| Tournigand, 2003 [19] |
109 |
FOLFIRI/FOLFOX6 |
14.2 |
21.5 |
| Hurwitz, 2004 [20] |
402 |
IFL/bevacizumab |
10.6 |
20.3 |
| Goldberg, 2006 [21] |
154 |
FOLFOX4 |
9.7 |
19.0 |
| Falcone, 2007 [13] |
122 |
FOLFOXIRI |
9.8 |
22.6 |
| Fuchs, 2008 [22,23] |
57 |
FOLFIRI/bevacizumab |
11.2 |
28.0 |
| Saltz, 2008 [24] |
699 |
FOLFOX4/bevacizumab |
9.4 |
21.3 |
| Hecht, 2009 [25] |
823 |
FOLFOX/FOLFIRI/bev |
11.4 |
24.5 |
| |
|
+ panitumumab |
10.0 |
19.4 |
| Tebbutt, 2010 [26] |
157 |
capecitabine/bevacizumab |
8.5 |
- |
| Stathopoulos, 2010 [27] |
114 |
IRI/5-FU/FA/bevacizumab |
- |
22.0 |
| |
108 |
IRI/5-FU/FA |
- |
25.0 |
| Douillard, 2010 [28] | 1183 | FOLFOX4/panitumumab | 9.6 | 23.9 |